Publications by authors named "Kathleen P Kemp"
Article Synopsis
- The study found that adding trastuzumab to chemotherapy improves survival rates for patients with HER2(+) breast cancer by enhancing immune responses not just targeted at HER2, but also to other related proteins.
- Analysis of blood samples from 48 women revealed that many had elevated antibodies to specific cancer-related proteins before treatment, and after receiving trastuzumab and chemotherapy, a significant majority (69%) showed increased antibody responses, which correlated with better progression-free survival (PFS) and overall survival (OS).
- Interestingly, patients with high preexisting immunity to HER2-ICD did not benefit from the treatment, highlighting a complex relationship between the immune response and treatment efficacy.
